Cost –Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong
ConclusionsDAAs can be a cost-effective option for the treatment of genotype 1 HCV patients in Hong Kong, and elbasvir/grazoprevir is cost-effective.
Source: Digestive Diseases and Sciences - Category: Gastroenterology Source Type: research
More News: Cancer & Oncology | Carcinoma | Cirrhosis | Clinical Trials | Gastroenterology | Hepatitis | Hepatitis C | Hepatocellular Carcinoma | Hong Kong Health | Liver | Liver Cancer | Liver Disease | Liver Transplant | Oral Cancer | Study | Transplant Surgery | Transplants | Urology & Nephrology | Virology